化疗联合乌苯美司对恶性肿瘤患者免疫功能的影响

Clinical observation on change of immunological function after chemotherapy in combination with ubenimex for malignant tumors

目的:探讨化疗联合乌苯美司治疗对恶性肿瘤患者免疫功能的影响。方法:采用FCM法分别对150例行化疗联合乌苯美司辅助治疗和150例单用化疗治疗的恶性肿瘤患者外周血中T淋巴细胞亚群和自然杀伤(natural killer,NK)细胞进行检测。结果:化疗联合乌苯美司治疗组患者外周血中CD3+、CD4+T淋巴细胞和NK细胞(CD3-/CD16+CD56+)所占的比例及CD4+/CD8+的比值明显高于单用化疗(对照)组,而CD8+T细胞所占比例则有所下降,低于对照组,差异均有统计学意义(P<0.05)。结论:乌苯美司能够有效提高化疗后患者机体的免疫功能。

Objective： To explore the effect of chemotherapy in combination with ubenimex on immunological function of patients with malignant tumors. Methods： The changes of counts of T-lymphocyte subsets and NK （natural killer） cells in peripheral blood of patients with malignant tumors after chemotherapy alone （n = 150） or in combination with ubenimex （n = 150） were examined by FCM （flow metry）. Results： The proportions of CD3＋ and CD4＋ T-lymphocyte subsets, NK cells （CD3-/CD16＋ CD56 ＋） and the ratio of CD4＋/CD8＋ in peripheral blood of patients with malignant tumors after chemotherapy in combination with ubenimex were significantly higher than those of patients receiving chemotherapy alone （P 〈 0.05）. The proportion of CD8＋ T-lymphocytes was obviously lower in patients receiving chemotherapy in combination with ubenimex than that in patients receiving chemotherapy alone （P 〈 0.05）. Conclusion： Use of ubenimex may improve the immunological function of patients with malignant tumors after chemotherapy.